Skip to content
Board of Directors
Lawrence Bruder
Noxilizer’s former President & CEO brings over 25 years of leadership and operational experience in large and small life science companies, including Becton Dickinson, Applied Biosystems, Leica, Olympus, and Guava Technologies. Prior to Noxilizer, he led venture-backed Guava Technologies, which was sold to Millipore Biosciences in 2009. Much of his experience prior to Guava was at Becton Dickinson, where he held a number of significant positions over a 10-year period. His responsibilities in both companies included the clinical and regulatory aspects of 510(k) submittals to the FDA for medical devices, significant commercial interaction with pharmaceutical companies, and high-level business development transactional activity. Mr. Bruder holds a B.S. from Rochester Institute of Technology and Master of Management in Marketing and Economics from the Kellogg School of Management at Northwestern University.
NewVale Capital
Rich Fante
Rich is an Executive Partner at NewVale Capital LLC. With more than 30 years of commercial pharmaceutical experience, he previously served as President & CEO of AstraZeneca US, where he led the company’s U.S. business operations. Rich also served as CEO of Innocoll, a specialty pharmaceutical company backed by Gurnet Point Capital. Over his career, Rich has built and led large commercial organizations, bringing deep expertise in strategy, operations, and leadership within the global pharmaceutical industry. He holds a BA from Princeton University and an MBA from the University of North Carolina at Chapel Hill.
NewVale Capital
Sami Hawwa
Sami is a Principal at NewVale Capital LLC. He has nearly 10 years of life sciences investing and advisory experience across private equity, growth investing, and investment banking. Prior to joining NewVale, Sami was a growth investor at CRG LP, focused on pharma and pharma services companies. Earlier in his career, he worked in investment banking at Cowen and Piper Jaffray, where he advised biotechnology clients on mergers and acquisitions, and growth financings. Sami holds an MS in Finance and a BA in Economics from Southern Methodist University, graduating cum laude and as a member of Phi Beta Kappa.
NewVale Capital
Todd Holmes
Todd is the Founder and Managing Partner of NewVale Capital LLC. He has more than 20 years of life science investing, company-building, and transaction experience across private and public sectors. Before founding NewVale, Todd led pharma and pharma services investing at CRG LP. Prior to CRG, he held senior investment roles with Gurnet Point Capital and Third Rock Ventures, helping to build and grow life science companies. Earlier in his career, he was an investor with BVF Partners, a biotechnology-focused hedge fund. Todd holds a BS in economics from Colgate University and an MBA from the Wharton School at the University of Pennsylvania.
PRESIDENT & CHIEF EXECUTIVE OFFICER
Christopher A. Thatcher
Christopher A. Thatcher was named Noxilizer’s President and CEO in May 2024. He is a seasoned business leader with over 25 years of experience driving and turning around revenue and earnings growth in the global medical device, equipment, pharmaceutical, and healthcare products sectors. His extensive leadership experience includes roles as President of Integra LifeSciences’ Neurosurgery Division, Country Manager of Canada at Bausch and Lomb and Vice President of Global Strategy and Commercial Development at Bausch & Lomb. Additionally, as President and CEO he successfully raised significant capital and took Neuronetics public in an IPO in 2018. Christopher also serves on the Board of Directors for Noxilizer, Micro Interventional Devices and Strategic Advisor for Sinaptica Therapeutics. Mr. Thatcher holds a B.A. from Lafayette College.